Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
Aclarion (NASDAQ: ACON) has received its 24th US patent through a Notice of Allowance from the USPTO. This patent expands the company's ability to use Magnetic Resonance Spectroscopy (MRS) for identifying propionic acid (PA) throughout the body as a potential biomarker for infection and pain. Previously, Aclarion's patents PA identification by MRS to intervertebral discs only.
The company's technology leverages MRS, a capability of common MRI scanners, to analyze chemical biomarkers within soft tissues. While traditional MRS post-processing faces challenges in generating quality data, Aclarion's patented innovations address these limitations, ensuring more reliable spectral data analysis for their Nociscan solution and other MRS applications.
Aclarion (NASDAQ: ACON) ha ricevuto il suo 24° brevetto statunitense tramite un Avviso di Concessione dall'USPTO. Questo brevetto amplia la capacità dell'azienda di utilizzare la Spettroscopia della Risonanza Magnetica (MRS) per identificare l'acido propionico (PA) in tutto il corpo come potenziale biomarcatore per infezioni e dolori. In precedenza, i brevetti di Aclarion riguardavano l'identificazione del PA tramite MRS solo per i dischi intervertebrali.
La tecnologia dell'azienda sfrutta la MRS, una funzione dei comuni scanner MRI, per analizzare i biomarcatori chimici all'interno dei tessuti molli. Mentre la tradizionale post-elaborazione della MRS affronta sfide nella generazione di dati di qualità, le innovazioni brevettate di Aclarion affrontano queste limitazioni, garantendo un'analisi più affidabile dei dati spettrali per la loro soluzione Nociscan e altre applicazioni MRS.
Aclarion (NASDAQ: ACON) ha recibido su 24° patente estadounidense a través de un Aviso de Aprobación por parte de la USPTO. Esta patente amplía la capacidad de la empresa para utilizar Espectroscopia de Resonancia Magnética (MRS) para identificar el ácido propiónico (PA) en todo el cuerpo como un posible biomarcador de infección y dolor. Anteriormente, las patentes de Aclarion se centraban en la identificación de PA mediante MRS solo para discos intervertebrales.
La tecnología de la empresa aprovecha la MRS, una capacidad de los escáneres de MRI comunes, para analizar biomarcadores químicos en los tejidos blandos. Mientras que el postprocesamiento convencional de MRS enfrenta desafíos en la generación de datos de calidad, las innovaciones patentadas de Aclarion abordan estas limitaciones, garantizando un análisis más fiable de datos espectrales para su solución Nociscan y otras aplicaciones de MRS.
Aclarion (NASDAQ: ACON)는 USPTO의 허가 통지를 통해 24번째 미국 특허를 받았습니다. 이 특허는 회사가 자기 공명 분광법 (MRS)을 사용하여 신체 전체에서 프로피온산(PA)을 식별할 수 있는 능력을 확장하여 감염과 통증의 잠재적 바이오마커로 활용할 수 있게 합니다. 이전에는 Aclarion의 특허가 MRS를 사용한 PA 식별을 오직 추간판에만 국한하였습니다.
회사의 기술은 일반 MRI 스캐너의 기능인 MRS를 이용하여 연조직 내 화학적 바이오마커를 분석합니다. 전통적인 MRS 후처리가 품질 데이터를 생성하는 데 어려움을 겪는 반면, Aclarion의 특허 혁신은 이러한 한계를 해결하여 Nociscan 솔루션 및 기타 MRS 응용 프로그램을 위한 보다 신뢰할 수 있는 스펙트럼 데이터 분석을 보장합니다.
Aclarion (NASDAQ: ACON) a reçu son 24ème brevet américain par le biais d'un Avis de Concession de l'USPTO. Ce brevet étend la capacité de l'entreprise à utiliser la Spectroscopie par Résonance Magnétique (MRS) pour identifier l'acide propionique (PA) dans tout le corps en tant que biomarqueur potentiel d'infection et de douleur. Auparavant, les brevets d'Aclarion concernaient uniquement l'identification du PA par MRS pour les disques intervertébraux.
La technologie de l'entreprise s'appuie sur la MRS, une capacité des scanners IRM courants, pour analyser les biomarqueurs chimiques au sein des tissus mous. Bien que le post-traitement traditionnel de la MRS soit confronté à des défis dans la génération de données de qualité, les innovations brevetées d'Aclarion répondent à ces limitations, garantissant une analyse des données spectrales plus fiable pour leur solution Nociscan et d'autres applications MRS.
Aclarion (NASDAQ: ACON) hat sein 24. US-Patent durch eine Genehmigungsmitteilung des USPTO erhalten. Dieses Patent erweitert die Fähigkeit des Unternehmens, Magnetresonanzspektroskopie (MRS) zur Identifizierung von Propionsäure (PA) im gesamten Körper als potenziellen Biomarker für Infektionen und Schmerzen zu nutzen. Zuvor beschränkten sich die Patente von Aclarion auf die PA-Identifikation durch MRS nur für zwischenwirbelplatten.
Die Technologie des Unternehmens nutzt MRS, eine Funktion gängiger MRI-Scanner, um chemische Biomarker in Weichgewebe zu analysieren. Während die traditionelle MRS-Nachbearbeitung Herausforderungen bei der Erzeugung von Qualitätsdaten gegenübersteht, adressieren die patentierten Innovationen von Aclarion diese Einschränkungen und gewährleisten eine zuverlässigere Analyse spektraler Daten für ihre Nociscan-Lösung und andere MRS-Anwendungen.
- Received 24th US patent expanding proprietary technology rights
- Technology expansion from disc-specific to whole-body applications
- Enhanced capabilities for infection and pain biomarker identification
- None.
Insights
The USPTO's Notice of Allowance for Aclarion's 24th patent marks a pivotal expansion of their intellectual property portfolio. This patent strategically broadens their rights from disc-specific propionic acid (PA) detection to whole-body applications, representing a significant competitive moat in the medical imaging space.
The expansion from spinal applications to whole-body PA detection could multiply Aclarion's total addressable market by an order of magnitude. The global medical imaging market, valued at over
Key technical advantages protected by this patent include:
- Enhanced MRS post-processing methods for more reliable chemical analysis
- Improved spectral data quality for sophisticated biomarker detection
- Broader applications for existing MRI infrastructure
While commercialization will require additional clinical validation and likely FDA clearances for new applications, the patent provides 20 years of exclusivity for these methods. This protection is particularly valuable as it builds upon their existing Nociscan platform, potentially allowing for faster market entry through the 510(k) pathway.
- Recent Notice of Allowance is for Aclarion’s 24th issued US patent
- Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an intervertebral disc
- Patent will expand Aclarion’s proprietary rights to use MRS to measure propionic acid as a biomarker for the identification of potential infection and pain throughout the body
BROOMFIELD, Colo., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent. Whereas previous issued patents in the Aclarion portfolio limit the use of propionic acid (PA) identification by magnetic resonance spectroscopy (MRS) to the disc, this new patent expands Aclarion’s ability to use MRS to identify PA throughout the body to identify potential sources of infection and pain.
“While propionic acid is a normal human physiological metabolite, there are many known side effects and disorders associated with propionic acid,” said Jeff Lotz, PhD, Vice Chair Research, University of California at San Francisco. “Aclarion is a global leader in harnessing the power of MR spectroscopy, and this recent patent addition further expands the potential for Aclarion to commercialize the use of MRS beyond discogenic low back pain to encompass identifying and measuring propionic acid throughout the body. The implications are profound.”
MRS is an existing capability of leading magnetic resonance imaging (MRI) scanners which are commonly used today for medical imaging. MRI creates images of the soft tissue structures of the body while MRS generates spectral data information on the levels of various chemical biomarkers within the soft tissues such as proteins, carbohydrates, acids, etc. However, conventional MRS post-processing approaches can be challenging and fall short of generating sufficient quality data for reliable chemical analysis. Several of Aclarion’s patents relate to novel inventions that address many of these challenges, resulting in more reliable, higher quality spectral data for more sophisticated chemical biomarker analysis, ensuring the accuracy and reliability of the Nociscan solution and other MRS applications.
To find a Nociscan center, view our site map here.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities of Aclarion, Inc. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
What is the significance of Aclarion's (ACON) new patent for MRS technology?
How many US patents does Aclarion (ACON) now hold in 2025?
What is the key biomarker that Aclarion's (ACON) new patent focuses on?
How does Aclarion's (ACON) MRS technology improve upon conventional methods?
